bioRxivCell Biology
Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes
A. Kim, J. G. Knudsen, J. C. Madara, A. Benrick, T. Hill, L. Abdul Kadir, J. A. Kellard, L. Mellander, C. Miranda, H. Lin, T. James, K. Suba, A. Spigelman, Y. Wu, P. MacDonald, I. Wernstedt Asterholm, T. Magnussen, M. Christensen, T. Vilsboll, V. Salem, F. K. Knop, P. Rorsman, B. B. Lowell, L. Briant
Abstract
Insulin-induced hypoglycemia is a major barrier to the treatment of type-1 diabetes (T1D). Accordingly, it is important that we understand the mechanisms regulating the circulating levels of glucagon - the bodys principal blood glucose-elevating hormone which is secreted from alpha-cells of the pancreatic islets. Varying glucose over the range of concentrations that occur physiologically between the fed and fuel-deprived states (from 8 to 4 mM) has no significant effect on glucagon secretion in isolated islets (in vitro) and yet associates with dramatic changes in plasma glucagon in vivo. The identity of the systemic factor(s) that stimulates glucagon secretion remains unknown. Here, we show that arginine-vasopressin (AVP), secreted from the posterior pituitary, stimulates glucagon secretion. Glucagon-secreting alpha-cells express high levels of the vasopressin 1b receptor gene (Avpr1b). Activation of AVP neurons in vivo increased circulating copeptin (the C-terminal segment of the AVP precursor peptide, a stable surrogate marker of AVP) and increased blood glucose; effects blocked by pharmacological antagonism of either the glucagon receptor or vasopressin 1b receptor. AVP also mediates the stimulatory effects of hypoglycemia produced by exogenous insulin and 2-deoxy-D-glucose on glucagon secretion. We show that the A1/C1 neurons of the medulla oblongata drive AVP neuron activation in response to insulin-induced hypoglycemia. Exogenous injection of AVP in vivo increased cytoplasmic Ca2+ in alpha-cells (implanted into the anterior chamber of the eye) and glucagon release. Hypoglycemia also increases circulating levels of AVP in humans and this hormone stimulates glucagon secretion from isolated human islets. In patients with T1D, hypoglycemia failed to increase both plasma copeptin and glucagon levels. These findings suggest that AVP is a physiological systemic regulator of glucagon secretion and that this mechanism becomes impaired in T1D.
- organism: human
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Effects of Arginine Vasopressin on Islet Cells in Pancreatic Tissue Slices: Glucose-Dependent Modulation of Alpha and Beta Cell Activity
Jasmina Kerčmar, Nastja Murko, … Marjan Slak Rupnik·bioRxiv·Mar 3, 2025
- Tmem117 in AVP neurons regulates the counterregulatory response to hypoglycemia
S. Gaspari, G. Labouebe, … B. Thorens·bioRxiv·Oct 21, 2022
- RESTORING GLUTAMATE RECEPTOR SIGNALING IN PANCREATIC ALPHA CELLS RESCUES GLUCAGON RESPONSES IN TYPE 1 DIABETES
J. K. Panzer, A. Tamayo, A. Caicedo·bioRxiv·Aug 11, 2021
- Gut-derived GLP-1 released by rare sugar D-allulose cooperates with insulin to activate left-sided vagal afferents and enhance insulin sensitivity
Kento Ohbayashi, Mamoru Tanida, … Yusaku Iwasaki·DiabetesPeer-reviewed·May 1, 2026
- Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes
M. Omar-Hmeadi, P.-E. Lund, … S. Barg·bioRxiv·Oct 1, 2019
- Glucose derived redox equivalents preserve PKA activity and glucagon secretion during hypoglycaemia
Alexander Frueh, Georgios Katzilieris‐Petras, … Jakob Grunnet Knudsen·bioRxiv·Aug 20, 2026